All Careers Advice
Sections
-
Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the category Operations with the 2024 Facility of the Year Awards (FOYA).
-
This year, the United States expects to tally more than two million new cancer diagnoses— a first-ever prediction— and more than 611,000 cancer-related deaths.
-
What Does a Clinical SAS Programmer Do?
4/16/2024
Within the realm of clinical research, a Statistical Analysis System (SAS) Programmer is responsible for managing, analysing, and interpreting clinical data utilising SAS software. This includes developing and applying statistical techniques to assess the efficacy, safety, and value of a pharmace... -
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
-
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Appro...
4/16/2024
Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra®** (tocilizumab). Tyenne®, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation. -
Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and B...
4/16/2024
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological ... -
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vert...
-
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox PCR Test Home Collection Kit to aid in the diagnosis of infection with non-variola Ortho...
-
In this recruiter guide, we explore the essential considerations for you to keep in mind when hiring a Biostatistician. From understanding the unique demands of the role to identifying key competencies and conducting effective interviews, this guide will help you to focus your candidate search an...
-
Clinical Data Management (CDM) has drastically transformed over the years, proactively adapting to technological advancements, changing regulations, and the growing complexity of clinical trials.
-
Bayer and Google Cloud today announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients.
-
About ProteoNic
4/9/2024
ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA. The company offers technology and services for the generation of cell lines and viral vectors with greatly improved production characteristics. -
Thermo Fisher Scientific Launches New ENERGY STAR certified TSX Universal Series ULT Freezers to ...
4/9/2024
Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers. -
As the life science industry becomes increasingly data-driven, the field of clinical data management (CDM) is expanding, offering a wealth of career opportunities for those interested in leveraging data to improve patient outcomes and healthcare processes.
-
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empaglif...
4/8/2024
The EMPACT-MI phase III clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalization due to heart failure or all-cause mortality for empagliflozin versus placebo, which did not reach statistical significance. -
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated ...
4/8/2024
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options. -
From understanding the unique demands of the role to identifying key competencies and conducting effective interviews, this guide will provide you with valuable tips to help you focus your candidate search and engage top talent.
-
Artificial Intelligence and Machine Learning in Clinical Data Management: Opportunities and Ethic...
4/4/2024
Artificial Intelligence (AI) and Machine Learning (ML) promise to revolutionise how clinical data is collected, analysed, and utilised, offering unprecedented opportunities for enhancing trial efficiency and patient outcomes. -
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acid...
4/4/2024
Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), has been published in Nature. -
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients With Platinum-R...
4/4/2024
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 Phase 2/3 trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in patients w...